Additional file 2: Fig. S2. The pan-cancer landscape of MED12 mutations across human tumors. The proportion of MED12 mutated tumors identified for each cancer type with alteration frequency in TCGA pan-cancer cohorts.

Additional file 2.

Additional file 2.

Additional file 3.

Additional file 3.

Additional file 1: Fig. S1. Flowchart of the study design. A. Merge of WES cohorts from five published studies (Hellman et al. [10], Rizvi et al. [11], Miao et al [12, 13], Allen et al. [14], Liu et al. [15]). B. MSKCC cohort from the published study (Samstein et al [16]). C. The TCGA dataset was used to perform DDR-related gene mutation, tumor-infiltrating immune cells and prognostic analyses.

Additional file 3: Fig. S3. Kaplan–Meier curves of OS between the MED12-Mut and wildtype groups in the TCGA cohort.

Additional file 3: Fig. S3. Kaplan–Meier curves of OS between the MED12-Mut and wildtype groups in the TCGA cohort.

Additional file 1: Fig. S1. Flowchart of the study design. A. Merge of WES cohorts from five published studies (Hellman et al. [10], Rizvi et al. [11], Miao et al [12, 13], Allen et al. [14], Liu et al. [15]). B. MSKCC cohort from the published study (Samstein et al [16]). C. The TCGA dataset was used to perform DDR-related gene mutation, tumor-infiltrating immune cells and prognostic analyses.

Additional file 2: Fig. S2. The pan-cancer landscape of MED12 mutations across human tumors. The proportion of MED12 mutated tumors identified for each cancer type with alteration frequency in TCGA pan-cancer cohorts.